BEAT HeartBeam Inc

CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical technology company with an initial focus on the diagnosis and monitoring of cardiac arrhythmias, today announced the pricing of 5,000,000 shares of outstanding common stock being offered by certain existing stockholders to the public at the price of $26.50 per share. CardioNet, Inc. will not receive any proceeds from the sale. The offer is expected to close on August 6, 2008. The selling stockholders have also granted to the underwriters a 30-day option to purchase from them an additional 750,000 shares to cover over-allotments, if any. Citi is the sole book-running manager, Banc of America Securities LLC and Leerink Swann are the co-lead managers and Cowen and Company and Thomas Weisel Partners LLC are the co-managers for this offering. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 31, 2008. This offering is being made by the existing stockholders solely by means of written prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, by contacting the Prospectus Department of Citi by calling (800) 831-9146, by emailing batprospectusdept@citigroup.com or by writing to Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220 or at the Securities and Exchange Commission�s website: http://www.sec.gov. This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Statements in this press release that are not strictly historical are �forward-looking� statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve a high degree of risk and uncertainty. In particular, due to market conditions or otherwise, the selling stockholders may be unable to complete the sale of common stock under the registration statement, and, even if such sale is completed, the underwriters for the offering may not exercise any portion of the over-allotment option. About CardioNet CardioNet, Inc. is a leading provider of ambulatory, continuous, real-time outpatient management solutions for monitoring relevant and timely clinical information regarding an individual�s health. CardioNet�s initial efforts are focused on the diagnosis and monitoring of cardiac arrhythmias with a solution that it markets as the CardioNet System. More information can be found at http://www.CardioNet.com.